Internal Medicine Residency Program, University of Washington School of Medicine, Seattle, Washington.
Hospital and Specialty Medicine Service, Veterans Affairs Puget Sound Health Care System, and Division of General Internal Medicine, University of Washington School of Medicine, Seattle, Washington.
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2398-2414.e3. doi: 10.1016/j.cgh.2019.07.051. Epub 2019 Jul 31.
Patients with cirrhosis are at increased risk of perioperative morbidity and mortality. We provide a narrative review of the available data regarding perioperative morbidity and mortality, risk assessment, and management of patients with cirrhosis undergoing non-hepatic surgical procedures.
We conducted a comprehensive review of the literature from 1998-2018 and identified 87 studies reporting perioperative outcomes in patients with cirrhosis. We extracted elements of study design and perioperative mortality by surgical procedure, Child-Turcotte-Pugh (CTP) class and Model for End-stage Liver Disease (MELD) score reported in these 87 studies to support our narrative review.
Overall, perioperative mortality is 2-10 times higher in patients with cirrhosis compared to patients without cirrhosis, depending on the severity of liver dysfunction. For elective procedures, patients with compensated cirrhosis (CTP class A, or MELD <10) have minimal increase in operative mortality. CTP class C patients (or MELD >15) are at high risk for mortality; liver transplantation or alternatives to surgery should be considered. Very little data exist to guide perioperative management of patients with cirrhosis, so most recommendations are based on case series and expert opinion. Existing risk calculators are inadequate.
Severity of liver dysfunction, medical comorbidities and the type and complexity of surgery, including whether it is elective versus emergent, are all determinants of perioperative mortality and morbidity in patients with cirrhosis. There are major limitations to the existing clinical research on risk assessment and perioperative management that warrant further investigation.
肝硬化患者围手术期发病率和死亡率均较高。我们对肝硬化患者行非肝脏手术围手术期发病率和死亡率、风险评估及管理的相关资料进行了综述。
我们对 1998 年至 2018 年的文献进行了全面检索,共检索到 87 项关于肝硬化患者围手术期结局的研究。我们对这些研究中手术方式、Child-Turcotte-Pugh(CTP)分级和终末期肝病模型(MELD)评分报告的围手术期死亡率和研究设计要素进行了提取,以支持我们的叙述性综述。
根据肝功能障碍的严重程度,与无肝硬化患者相比,肝硬化患者围手术期死亡率高 2-10 倍。对于择期手术,代偿性肝硬化(CTP 分级 A 或 MELD<10)患者手术死亡率略有增加。CTP 分级 C 患者(或 MELD>15)死亡率较高,应考虑肝移植或手术替代治疗。目前几乎没有数据可以指导肝硬化患者的围手术期管理,因此大多数建议都是基于病例系列和专家意见。现有的风险计算器也不够完善。
肝功能障碍严重程度、并存的医学合并症以及手术类型和复杂性,包括是否为择期手术与急诊手术,均为肝硬化患者围手术期发病率和死亡率的决定因素。目前关于风险评估和围手术期管理的临床研究存在重大局限性,需要进一步研究。